Notch1基因在淋巴细胞肿瘤中的表达变化及其意义  

Expression and Significance of Notch1 in Lymphoid Malignancies

作　　者：郑海涛[1] 李扬秋[1,2] 陈少华[1] 杨力建[1] 钟立业[1] 

机构地区：[1]暨南大学医学院血液病研究所,广州510632 [2]暨南大学医学院再生医学教育部重点实验室

出　　处：《肿瘤防治研究》2010年第10期1140-1143,共4页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金资助项目(30871091)

摘　　要：目的了解Notch1基因在淋巴细胞肿瘤中的表达特点。方法采用SYBRGreenⅠ荧光定量PCR和相对定量分析法检测43例淋巴细胞肿瘤患者(T细胞急性淋巴细胞白血病7例、T细胞非霍奇金淋巴瘤6例、B细胞急性淋巴细胞白血病9例、B细胞慢性淋巴细胞白血病5例和B细胞非霍奇金淋巴瘤16例)和20例健康人外周血单个核细胞的Notch1基因表达水平,以β2微球蛋白基因(β2M)作为内参,采用公式2-ΔCt×100%计算Notch1基因表达水平。结果 T细胞肿瘤组(中位数0.897%)与B细胞肿瘤组(中位数0.726%)患者外周血单个核细胞Notch1基因表达均比健康对照组(中位数0.288%)明显上升(P<0.01,P<0.01)。T细胞肿瘤组Notch1基因表达水平与B细胞肿瘤组的差异无统计学意义(P>0.05)。但五种类型淋巴细胞肿瘤Notch1基因表达水平有所不同,其中以B细胞慢性淋巴细胞白血病组最高,其次是T细胞非霍奇金淋巴瘤组,而B细胞非霍奇金淋巴瘤组的Notch1基因表达水平最低。结论异常高表达的Notch1基因可能与参与淋巴细胞肿瘤的发生发展过程,研究结果为靶向抑制Notch1的基因治疗提供初步依据。Objective To investigate the expression level of Notch1 gene in patients with lymphoid malignancies.Methods Real-time PCR with SYBR GreenⅠ technique was used to detect Notch1 gene expression level in peripheral blood mononuclear cells of 43 patients with lymphoid malignancies,including 7 cases with T-ALL,6 cases with T-NHL,9 cases with B-ALL,5 cases with B-CLL,16 cases with B-NHL] and 20 healthy individuals.β2-microglobulin gene（β2M） was used as an endogenous control.Relative level of Notch1 gene expression were analysed by the 2-ΔCt×100% method.Results The expression level of Notch1 in both T-cell lymphoid malignancies group（Median：0.897%） and B-cell lymphoid malignancies group（Median：0.726%） was significant higher than that in the healthy control（Median：0.288%）（P0.01,P0.01）.However,the expression level of Notch1 was different in the five types of lymphoid malignancies.The highest level was observed in the B-CLL group,secondary in the T-NHL group,the lowest in the B-NHL group.Conclusions The abnormal expression of Notch1 might played an important role in the pathogenesis of lymphoid malignancies.The result provided the preliminary basis for targeting the Notch1 pathways.

关 键 词：NOTCH1基因 实时定量PCR 淋巴细胞肿瘤 

分 类 号：R733.4[医药卫生—肿瘤] R733.7[医药卫生—临床医学]